These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 30355669)

  • 1. Isolation and Characterization of the Novel Botulinum Neurotoxin A Subtype 6.
    Moritz MS; Tepp WH; Bradshaw M; Johnson EA; Pellett S
    mSphere; 2018 Oct; 3(5):. PubMed ID: 30355669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative functional analysis of mice after local injection with botulinum neurotoxin A1, A2, A6, and B1 by catwalk analysis.
    Moritz MS; Tepp WH; Inzalaco HN; Johnson EA; Pellett S
    Toxicon; 2019 Sep; 167():20-28. PubMed ID: 31181297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes.
    Pellett S; Bradshaw M; Tepp WH; Pier CL; Whitemarsh RCM; Chen C; Barbieri JT; Johnson EA
    mBio; 2018 Mar; 9(2):. PubMed ID: 29588398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purification and Characterization of Botulinum Neurotoxin FA from a Genetically Modified Clostridium botulinum Strain.
    Pellett S; Tepp WH; Bradshaw M; Kalb SR; Dykes JK; Lin G; Nawrocki EM; Pier CL; Barr JR; Maslanka SE; Johnson EA
    mSphere; 2016; 1(1):. PubMed ID: 27303710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation and functional characterization of the novel Clostridium botulinum neurotoxin A8 subtype.
    Kull S; Schulz KM; Weisemann J; Kirchner S; Schreiber T; Bollenbach A; Dabrowski PW; Nitsche A; Kalb SR; Dorner MB; Barr JR; Rummel A; Dorner BG
    PLoS One; 2015; 10(2):e0116381. PubMed ID: 25658638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro.
    Whitemarsh RC; Tepp WH; Bradshaw M; Lin G; Pier CL; Scherf JM; Johnson EA; Pellett S
    Infect Immun; 2013 Oct; 81(10):3894-902. PubMed ID: 23918782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purification and characterization of a novel subtype a3 botulinum neurotoxin.
    Tepp WH; Lin G; Johnson EA
    Appl Environ Microbiol; 2012 May; 78(9):3108-13. PubMed ID: 22367089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translocation domain of botulinum neurotoxin A subtype 2 potently induces entry into neuronal cells.
    Kohda T; Tsukamoto K; Torii Y; Kozaki S; Mukamoto M
    Microbiol Immunol; 2020 Jul; 64(7):502-511. PubMed ID: 32301520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum neurotoxin X lacks potency in mice and in human neurons.
    Gregg BM; Matsumura T; Wentz TG; Tepp WH; Bradshaw M; Stenmark P; Johnson EA; Fujinaga Y; Pellett S
    mBio; 2024 Mar; 15(3):e0310623. PubMed ID: 38347673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo onset and duration of action varies for botulinum neurotoxin A subtypes 1-5.
    Pellett S; Tepp WH; Whitemarsh RC; Bradshaw M; Johnson EA
    Toxicon; 2015 Dec; 107(Pt A):37-42. PubMed ID: 26130522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of ELISA as endpoint in neuronal cell-based assay for BoNT detection using hiPSC derived neurons.
    Pellett S; Tepp WH; Johnson EA; Sesardic D
    J Pharmacol Toxicol Methods; 2017 Nov; 88(Pt 1):1-6. PubMed ID: 28465161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1.
    Pier CL; Chen C; Tepp WH; Lin G; Janda KD; Barbieri JT; Pellett S; Johnson EA
    FEBS Lett; 2011 Jan; 585(1):199-206. PubMed ID: 21126520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of Botulinum Neurotoxin Synthesis and Toxin Complex Formation by Arginine and Glucose in Clostridium botulinum ATCC 3502.
    Fredrick CM; Lin G; Johnson EA
    Appl Environ Microbiol; 2017 Jul; 83(13):. PubMed ID: 28455330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing toxin-based vaccines against botulism.
    Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
    Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comprehensive Structural Analysis of
    Gregory KS; Acharya KR
    Toxins (Basel); 2023 Jan; 15(2):. PubMed ID: 36828407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of gene expression in induced pluripotent stem cell-derived human neurons exposed to botulinum neurotoxin A subtype 1 and a type A atoxic derivative.
    Scherf JM; Hu XS; Tepp WH; Ichtchenko K; Johnson EA; Pellett S
    PLoS One; 2014; 9(10):e111238. PubMed ID: 25337697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substrate cleavage and duration of action of botulinum neurotoxin type FA ("H, HA").
    Pellett S; Tepp WH; Lin G; Johnson EA
    Toxicon; 2018 Jun; 147():38-46. PubMed ID: 29273248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of botulinum neurotoxin type D (strain 1873) in human neurons.
    Pellett S; Tepp WH; Scherf JM; Pier CL; Johnson EA
    Toxicon; 2015 Jul; 101():63-9. PubMed ID: 25937339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of extracellular and intracellular potency of botulinum neurotoxins.
    Cai F; Adrion CB; Keller JE
    Infect Immun; 2006 Oct; 74(10):5617-24. PubMed ID: 16988237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High resolution crystal structures of Clostridium botulinum neurotoxin A3 and A4 binding domains.
    Davies JR; Rees J; Liu SM; Acharya KR
    J Struct Biol; 2018 May; 202(2):113-117. PubMed ID: 29288126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.